Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autogene cevumeran + Atezolizumab in ctDNA+ NSCLC
NCT04267237Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
A Phase 2 trial of autogene cevumeran in non-small cell lung cancer (NSCLC), sponsored by Roche. Planned start Mar 2021; status: withdrawn.
02
Drugs
autogene cevumeran
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04267237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267237.